Department of Preventive Medicine, Mount Sinai School of Medicine, One Gustave Levy Place, Box 1057, New York, NY 10029, USA.
BMJ. 2011 Oct 11;343:d5621. doi: 10.1136/bmj.d5621.
To determine the prevalence of financial conflicts of interest among members of panels producing clinical practice guidelines on screening, treatment, or both for hyperlipidaemia or diabetes.
Cross sectional study.
Relevant guidelines published by national organisations in the United States and Canada between 2000 and 2010.
Members of guideline panels.
Prevalence of financial conflicts of interest among members of guideline panels and chairs of panels.
Fourteen guidelines met our search criteria, of which five had no accompanying declaration of conflicts of interest by panel members. 288 panel members had participated in the guideline development process. Among the 288 panel members, 138 (48%) reported conflicts of interest at the time of the publication of the guideline and 150 (52%) either stated that they had no such conflicts or did not have an opportunity to declare any. Among 73 panellists who formally declared no conflicts, 8 (11%) were found to have one or more. Twelve of the 14 guideline panels evaluated identified chairs, among whom six had financial conflicts of interest. Overall, 150 (52%) panel members had conflicts, of which 138 were declared and 12 were undeclared. Panel members from government sponsored guidelines were less likely to have conflicts of interest compared with guidelines sponsored by non-government sources (15/92 (16%) v 135/196 (69%); P<0.001).
The prevalence of financial conflicts of interest and their under-reporting by members of panels producing clinical practice guidelines on hyperlipidaemia or diabetes was high, and a relatively high proportion of guidelines did not have public disclosure of conflicts of interest. Organisations that produce guidelines should minimise conflicts of interest among panel members to ensure the credibility and evidence based nature of the guidelines' content.
确定在制定有关血脂异常或糖尿病筛查、治疗或两者兼有的临床实践指南的专家组中，成员存在财务利益冲突的比例。
横断面研究。
在美国和加拿大的国家组织在 2000 年至 2010 年期间发表的相关指南。
指南专家组的成员。
指南专家组和专家组组长成员中存在财务利益冲突的比例。
符合我们搜索标准的指南有 14 个，其中 5 个指南没有伴随成员利益冲突的声明。有 288 名指南小组成员参与了指南的制定过程。在 288 名小组成员中，138 名（48%）在指南发布时报告存在利益冲突，而 150 名（52%）要么表示没有利益冲突，要么表示没有机会申报。在正式宣布无冲突的 73 名小组成员中，有 8 名（11%）被发现存在一个或多个冲突。在 14 个指南小组中，有 12 个小组评估确定了组长，其中 6 名组长存在财务利益冲突。总的来说，150 名（52%）小组成员存在利益冲突，其中 138 名被申报，12 名未被申报。与非政府来源赞助的指南相比，政府赞助的指南的小组成员更不可能存在利益冲突（15/92（16%）比 135/196（69%）；P<0.001）。
在制定血脂异常或糖尿病临床实践指南的专家组中，财务利益冲突及其成员申报不足的比例很高，而且相当多的指南没有公开披露利益冲突。制定指南的组织应尽量减少小组成员之间的利益冲突，以确保指南内容的可信度和基于证据。
Zotero 插件